Summit Therapeutics Inc

Summit Therapeutics Inc

SMMT

Market Cap$14.59B
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Summit Therapeutics IncSummit Therapeutics Inc-60.6--70%--

Earnings Call Q1 2025

May 2, 2025 - AI Summary

Regulatory Milestones and Clinical Developments: Summit Therapeutics' partner Akeso has received approval for ivonescimab as a frontline monotherapy treatment for non-small cell lung cancer (NSCLC) in China, marking a significant regulatory achievement. The therapy demonstrated a 39% positive trend in overall survival during an interim analysis compared to pembrolizumab, indicating ivonescimab's potential to improve patient outcomes and solidify its competitive position.
Upcoming Clinical Data and Expectations: The HARMONi global Phase III trial, targeting EGFR mutated advanced NSCLC after third-generation tyrosine kinase inhibitor treatment, is expected to report top line data in mid-2025. This data will assess both progression-free survival and overall survival, crucial in evaluating ivonescimab's efficacy and establishing its market potential in Western regions, especially against existing therapies that have been unsuccessful in this setting.
Commercial Strategy and Team Expansion: Summit has strengthened its commercial capabilities by appointing Robert LaCaze as Chief Commercial Officer, with experience in launching and managing oncology products. This indicates the company’s preparation for a potential market launch of ivonescimab and aims to optimize penetration in the multi-billion dollar NSCLC market.

Exclusive for Stockcircle Pro members

Sign upSign Up
$39.00

Target Price by Analysts

95.5% upsideSummit Therapeutics Target Price DetailsTarget Price
$0.18

Current Fair Value

99.1% downside

Overvalued by 99.1% based on the discounted cash flow analysis.

Share Statistics

Market cap$14.59 Billion
Enterprise Value$14.39 Billion
Dividend Yield$0 (0%)
Earnings per Share$-0.31
Beta-1.05
Outstanding Shares738,076,000

Return

Return on Equity-
Return on Assets-
Return on Invested Capital-

Valuation & Multiples

P/E Ratio-60.64
PEG-135.6
Price to Sales-
Price to Book Ratio-
Enterprise Value to Revenue-
Enterprise Value to EBIT-89.93
Enterprise Value to Net Income-60
Total Debt to Enterprise0
Debt to Equity0.02

Revenue Sources

No data

Insider Trades

ESG Score

No data

About Summit Therapeutics Inc